BOSTON – Harvard Medical School affiliate Hebrew SeniorLife, a nonprofit organization committed to improving the lives of older adults, today announced that Douglas P. Kiel, M.D., M.P.H., Director, Musculoskeletal Research Center and Senior Scientist, Hinda and Arthur Marcus Institute for Aging Research, and a Professor of Medicine at Harvard Medical School, has been selected as the recipient of the American Society for Bone and Mineral Research (ASBMR) 2019 Frederic C. Bartter Award. This prestigious award is bestowed upon an ASBMR member in recognition of outstanding clinical investigation in disorders of bone and mineral metabolism.
“Throughout his 25 years with Hebrew SeniorLife and the Hinda and Arthur Marcus Institute for Aging Research, Doug has conducted multiple randomized controlled clinical trials to test the efficacy of treatments for osteoporosis and falls as well as starting the Framingham Osteoporosis Study,” said Lewis A. Lipsitz, M.D., Director, the Hinda and Arthur Marcus Institute for Aging Research & Chief Academic Officer, Hebrew SeniorLife. “He is a true leader who collaborates with others worldwide to understand how osteoporosis and loss of muscle mass and strength occur with aging. We are proud to have Doug working on this crucial research and congratulate him on this award.”
“Frederic C. Bartter, M.D., was one of the finest scientists and clinical investigators in academic medicine,” said, Bart L. Clarke, M.D., President, ASBMR. “Since 1986 we have annually recognized scientists and clinical investigators who demonstrate outstanding clinical investigation in disorders of bone and mineral metabolism. We are pleased to recognize Douglas P. Kiel as this year’s esteemed award recipient.”
A celebration honoring award recipients will be held during the ASBMR 2019 Annual Meeting on Saturday, September 21, 2019 from 8:00 – 8:30 a.m. in the Valencia Ballroom B-D at the Orange County Convention Center in Orlando, Florida.
About Douglas P. Kiel, M.D., M.P.H.
Dr. Kiel's research focuses on the epidemiology of osteoporosis and related fractures, including lifestyle factors, biomarkers, and genetic factors. He is also interested in sarcopenia and its consequences, including falls and disability. Dr. Kiel has conducted multiple clinical trials targeting the musculoskeletal system. He leads the Framingham Osteoporosis Study, and serves in leadership roles for many organizations including the NIH, American Society for Bone and Mineral Research, National Osteoporosis Foundation, and the Joint Commission. Dr. Kiel also heads the Geriomics program as a part of the Musculoskeletal Research Center at the Marcus Institute. The program includes faculty and post-doctoral fellows appointed through Harvard Medical School who study the "omics" of age-related disease, primarily diseases of the musculoskeletal system, as well as the aging process itself.
About Hebrew SeniorLife
Hebrew SeniorLife, a Harvard Medical School affiliate, is a national senior services leader dedicated to rethinking, researching, and redefining the possibilities of aging. The Boston-based nonprofit, founded in 1903, provides communities and health care for seniors, research into aging, and education for geriatric care providers. Visit http://www.hebrewseniorlife.org, follow us on Twitter @H_SeniorLife, like us on Facebook, or read our blog.
Hebrew SeniorLife’s Hinda and Arthur Marcus Institute for Aging Research is committed to the conduct of high-quality research that discovers the mechanisms of age-related disease and disability; leads to the prevention, treatment and cure of disease; advances the standard of care for older people; and informs public decision making.